SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AXYS Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: David Bogdanoff who wrote (352)11/18/1999 11:49:00 AM
From: bob zagorin  Respond to of 455
 
i agree. AXPH seems to be working very hard to streamline and focus on their core areas. I've always been attracted to AXPH because of the tryptase inhibitor program as my mother died of asthma and i know asthma is increasing. the second half of the announcement, although the subjecy is bowel disorders, is of more interest to me because of the tryptase-mast cell connection.



To: David Bogdanoff who wrote (352)11/18/1999 3:32:00 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 455
 
of course, maybe it shouldn't have been started in the first place........

Message 9772591

Agree with your conclusion, David, but enough is enough. Arris -----> AXPH has been micro-managed into marked underperformance.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News